Source: FiercePharma

TEVA Pharmaceuticals: Teva CEO Schultz took a big pay cut last year-but he bagged a contract extension, too

Teva has undergone a massive transformation in the past two years after a $3 billion restructuring fundamentally reshaped the Israeli drugmaker's operations. The man who led that charge, CEO Kåre Schultz, saw a big pay cut last year but will take solace with an extension that will keep him on board until at least 2023.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue


Kaare Schultz's photo - President & CEO of TEVA Pharmaceuticals

President & CEO

Kaare Schultz

CEO Approval Rating


Teva is a pharmaceutical company that researches and commercializes generic tablets and capsules for respiratory and cen... Read more